BLOG

Martin Turcotte, Scientific Liaison, Altasciences, recaps two notable talks on cell and gene therapy from the 2024 Boston Society Cell and Gene Therapy Conference.

Early-phase drug development is a complex process. Discover how Altasciences, as an integrated CRO/CDMO, alleviates the challenges and reduces risks.

Explore emerging areas of drugs from psychedelics and gene therapy, oligonucleotides to GLP-1RA for metabolic disorders.

Can the drug development industry change for the better? We dive into the obstacles and inefficiencies of the traditional outsourcing paradigm, and discuss how Altasciences offers an alternative to help sponsors safely accelerate their R&D.

Explore the significance of cytokines and the complement system, and the platforms Altasciences uses for monitoring and mitigating adverse effects.